newsfilter
← Latest News
Business Wire·

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

Updated Activity Data from Phase 1b Portion of the Study Shows Continued Improvement in Both Objective and Complete Response Rates Update Includes Response Data for Sub-Group of Patients Who Are Rituximab-Refractory and with POD24 Epizyme, Inc. (N